<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">JCI Insight</journal-id>
<journal-id journal-id-type="iso-abbrev">JCI Insight</journal-id>
<journal-id journal-id-type="publisher-id">JCI Insight</journal-id>
<journal-title-group>
<journal-title>JCI Insight</journal-title>
</journal-title-group>
<issn pub-type="epub">2379-3708</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28422756</article-id>
<article-id pub-id-type="pmc">5396523</article-id>
<article-id pub-id-type="publisher-id">90547</article-id>
<article-id pub-id-type="doi">10.1172/jci.insight.90547</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><bold>β</bold>-catenin and PI3K<bold>δ</bold> inhibition expands precursor Th17 cells with heightened stemness and antitumor activity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Majchrzak</surname>
<given-names>Kinga</given-names>
</name>
<email>kinga_majchrzak@sggw.pl</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nelson</surname>
<given-names>Michelle H.</given-names>
</name>
<email>nelsonmh@musc.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bowers</surname>
<given-names>Jacob S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bailey</surname>
<given-names>Stefanie R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wyatt</surname>
<given-names>Megan M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wrangle</surname>
<given-names>John M.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rubinstein</surname>
<given-names>Mark P.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Varela</surname>
<given-names>Juan C.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Zihai</given-names>
</name>
<email>zihai@musc.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Himes</surname>
<given-names>Richard A.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chan</surname>
<given-names>Sherine S.L.</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paulos</surname>
<given-names>Chrystal M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA.</aff>
<aff id="A2"><label>2</label>Department of Physiological Sciences, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Warsaw, Poland.</aff>
<aff id="A3"><label>3</label>Department of Surgery,</aff>
<aff id="A4"><label>4</label>Department of Dermatology and Dermatologic Surgery, and</aff>
<aff id="A5"><label>5</label>Department of Hematology and Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.</aff>
<aff id="A6"><label>6</label>Department of Chemistry and Biochemistry, College of Charleston, Charleston, South Carolina, USA.</aff>
<aff id="A7"><label>7</label>Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.</aff>
<aff id="A8"><label>8</label> Neuroene Therapeutics, Mount Pleasant, South Carolina, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Kinga Majchrzak or Chrystal M. Paulos, Hollings Cancer Center, MUSC, 86 Jonathan Lucas Street, Charleston South Carolina, 29425, USA. Phone: 843.792.8926; E-mail: <email>kinga_majchrzak@sggw.pl</email> (K. Majchrzak). Phone: 202.557.1868; E-mail: <email>paulos@musc.edu</email> (C.M. Paulos).</corresp>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> C.M. Paulos has a patent on ICOS signaling in adoptive T cell transfer therapy (US 9133436). C.M. Paulos, K. Majchrzak, and J.S. Bowers have a patent on pharmaceutical drug combinations or genetic strategies that instill durable antitumor T cell memory and activity (patent application P1685). R.A. Himes is the CSO of Neuroene Therapeutics and S.S.L. Chan is the COO of Neuroene Therapeutics.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2017-04-20T09:00:00-0400" publication-format="electronic">
<day>20</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date date-type="collection" iso-8601-date="2017-04-20T09:00:00-0400" publication-format="electronic">
<day>20</day>
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>20</day>
<month>4</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 0 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
<volume>2</volume>
<issue>8</issue>
<elocation-id>e90547</elocation-id>
<history>
<date date-type="received">
<day>6</day>
<month>9</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>3</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017, American Society for Clinical Investigation</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://insight.jci.org/articles/view/90547">This article is available online at https://insight.jci.org/articles/view/90547</self-uri>
<abstract>
<p>ICOS costimulation generates Th17 cells with durable memory responses to tumor. Herein, we found that ICOS induces PI3K/p110δ/Akt and Wnt/β-catenin pathways in Th17 cells. Coinhibiting PI3Kδ and β-catenin altered the biological fate of Th17 cells. Th17 cells inhibited of both pathways expressed less RORγt, which, in turn, reduced their ability to secrete IL-17. Unexpectedly, these cells were more effective (than uninhibited cells) at regressing tumor when infused into mice, leading to long-term curative responses. PI3Kδ inhibition expanded precursor Th17 cells with a central memory phenotype that expressed nominal regulatory properties (low FoxP3), while β-catenin inhibition enhanced Th17 multifunctionality in vivo. Remarkably, upon TCR restimulation, RORγt and IL-17 rebounded in Th17 cells treated with PI3Kδ and β-catenin inhibitors. Moreover, these cells regained β-catenin, Tcf7, and Akt expression, licensing them to secrete heightened IL-2, persist, and eradicate solid tumors without help from endogenous NK and CD8 T cells. This finding shines a light on ways to repurpose FDA-approved drugs to augment T cell–based cancer immunotherapies.</p>
</abstract>
<abstract abstract-type="toc">
<p>Inhibiting Wnt/β-catenin and PI3K/p110δ signaling pathways augments the antitumor activity of precursor stem memory Th17 cells in mice bearing large and poorly immunogenic tumors.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>